Trials / Recruiting
RecruitingNCT06344156
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Adjuvant Therapy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in Patients With Resected Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy | Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
- First posted
- 2024-04-03
- Last updated
- 2025-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06344156. Inclusion in this directory is not an endorsement.